GRFS earnings date and last-quarter result: last quarter beat, P/E 15.59. Updated 2026-07-23.
Grifols (GRFS) Research Hub
Grifols (GRFS) trades on NASDAQ, ES in the Healthcare (Drug Manufacturers - General) sector. As of 2026-10-26, shares last closed at 7.92 USD (+4.76%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 15.59, market cap 6.61B. This hub links to the full technical, earnings and options research available for GRFS.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Drug Manufacturers - General) |
|---|---|
| Exchange | NASDAQ, ES |
| Last close | 7.92 USD (+4.76%) |
| 52-week range | 7.02 USD – 8.38 USD |
| Trend regime | Range |
| 14-day RSI | 62.7 (Bullish) |
| Trailing P/E | 15.59 |
| Market cap | 6.61B |
| Dividend yield | 0.70% |
Available research for GRFS
Covered Call on GRFS: how it works, illustrative setup around the real 7.92 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on GRFS: how it works, illustrative setup around the real 7.92 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on GRFS: how it works, illustrative setup around the real 7.92 USD price, max profit/loss, breakeven and when to use it. Educational.
GRFS technical analysis: range, last 7.92 USD, RSI 62.7, 52w range 7.02 USD–8.38 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is GRFS in?
Grifols (GRFS) is classified under Healthcare (Drug Manufacturers - General), listed on NASDAQ, ES.
Is GRFS in an uptrend or downtrend?
As of 2026-10-26, GRFS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is GRFS's trailing P/E ratio?
GRFS's trailing P/E is 15.59, with a market cap of 6.61B. See the earnings research page for full valuation detail.